Patent details

Basic Information

Publication number:

93015

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP057844847

Legal Status:

Active

Application number:

93015

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/15/1060 - Kyprolis -carfilzomib

Marketing Authorization Type:

Marketing Authorization Date:

23/11/2015

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Dates

Filing date:

06/04/2016

First Marketing Authorization date:

23/11/2015

Grant date:

06/06/2016

Activation date:

08/08/2025

Publication date:

06/06/2016

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

08/08/2030

SPC Extension Expiration:

08/08/2030

Rejection date:

Withdrawal date:

Owner

From:

20/04/2016

 

 

Name:

ONYX THERAPEUTICS, INC.

Address:

249 E. GRAND AVENUE, SOUTH SAN FRANCISCO, CA 94080, United States (US)

History of Owners

From:

06/04/2016

To:

19/04/2016

Name:

Onyx Therapeutics Inc.

Address:

c/o Onyx Pharmaceuticals, Inc. 2100 Powell Street, Emeryville, CA 94608, United States (US)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

06/04/2016

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Inventor

1

Name:

LAIDIG Guy, J.

Address:

United States (US)

2

Name:

SMYTH Mark, S.

Address:

United States (US)

Publication

Bulletin

Bulletin Heading:

SPC3

Bulletin edition number:

2025/10

Publication date:

05/09/2025

Description:

Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:

31/08/2026

Annual Fee Number:

22

Annual Fee Amount:

420 Euro

Expected Payer:

Last Annual Fee Payment Date:

23/07/2025

Last Annual Fee Paid Number:

21

Last Annual Fee Paid Amount:

410 Euro

Payer:

ANAQUA SERVICES (ANC. SGA2)

Filing date	Document type	Number of pages